Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Aug;9(8):585-8.
doi: 10.1093/europace/eum059. Epub 2007 Apr 26.

The Arg389Gly beta1-adrenergic receptor gene polymorphism and susceptibility to faint during head-up tilt test

M F Márquez  1 , Guadalupe Hernández-Pacheco, Antonio G Hermosillo, Jorge R Gómez, Manuel Cárdenas, Gilberto Vargas-Alarcón
Affiliations

The Arg389Gly beta1-adrenergic receptor gene polymorphism and susceptibility to faint during head-up tilt test

M F Márquez et al. Europace. 2007 Aug.

Abstract

Aims: To investigate the association of the Gly389 allele with positive head-up tilt test (HUT) in a Mexican Mestizo population.

Methods and results: HUT results were compared between carriers (one or two copies of the Gly389 allele) and non-carriers (Arg389Arg genotype) of the Gly389 allele of the beta(1)AR gene in 50 patients with unexplained syncope. Thirty-three patients (66%) had a positive HUT. Patients with a positive HUT had a higher Gly389 allele frequency compared with those with a negative test (30.3 vs. 3%; OR 13; pC = 0.012). Moreover, when comparing positive HUT in passive drug-free phase, positive HUT in pharmacological (nitrate) phase, and negative (both phases), a decreasing gradient in the frequencies of the Gly389 allele was found among the three groups: 45.4, 22.7, and 3%, respectively.

Conclusion: An association of positive tilt table testing to a single nucleotide polymorphism with a Gly to Arg switch at position 389 of the beta(1)AR was found. This polymorphism may contribute to susceptibility to faint during orthostatic challenge.

PubMed Disclaimer

Publication types

Substances